Abbott Laboratories, a key player in the healthcare products sector, reported robust third-quarter results on Wednesday, exceeding market expectations in both sales and earnings. This positive performance was largely attributed to the company’s thriving medical-devices division. The Abbott Park, Illinois-based company has also raised its earnings guidance for the year, showcasing its confidence in sustained growth.<\/p>\n
For the third quarter of the fiscal year, Abbott (ABT) posted a net income of $1.646 billion<\/strong>, translating to 94 cents per share<\/strong>, a significant increase from $1.436 billion<\/strong> or 82 cents per share<\/strong> reported in the same quarter of the previous year. On an adjusted basis, the earnings amounted to $1.21 per share<\/strong>, surpassing the FactSet consensus estimate of $1.20<\/strong>.<\/p>\n Total sales reached $10.635 billion<\/strong>, reflecting a notable rise from $10.143 billion<\/strong> in the previous year\u2019s third quarter. Analysts had anticipated sales of approximately $10.551 billion<\/strong>, indicating that Abbott has performed favorably amidst a competitive market.<\/p>\n Abbott’s medical-device sector emerged as a significant contributor to the overall performance, generating $4.747 billion<\/strong> in revenue for the quarter, representing an increase of 11.7%<\/strong> compared to the prior year. This segment\u2019s growth underscores the company\u2019s strategic focus on innovative healthcare solutions.<\/p>\n In contrast, the company\u2019s nutrition division reported sales of $2.066 billion<\/strong>, which represented a slight decrease of 0.3%<\/strong> year-over-year. Abbott attributed this decline to the discontinuation of its ZonePerfect product line, which was phased out in March 2024.<\/p>\n When looking at the diagnostics segment, Abbott reported revenue of $2.412 billion<\/strong> for the quarter. As anticipated, the growth was somewhat hindered by declines in year-over-year COVID-19 diagnostic sales, which totaled $265 million<\/strong>, down from $305 million<\/strong> in the third quarter of the prior year. However, excluding COVID-19 testing-related sales, Abbott\u2019s global diagnostics revenue grew 0.2%<\/strong> on a reported basis and by 3.3%<\/strong> organically.<\/p>\n In light of its strong third-quarter performance, Abbott adjusted its full-year earnings outlook. The new forecast provides a range for earnings between $3.34<\/strong> and $3.40<\/strong> per share, up from a prior estimate of $3.30<\/strong> to $3.40<\/strong>. Additionally, Abbott improved its adjusted earnings guidance to between $4.64<\/strong> and $4.70<\/strong> per share, compared to the earlier range of $4.61<\/strong> to $4.71<\/strong>.<\/p>\n Abbott also maintained its forecast for organic sales growth in 2024, projecting an increase between 9.5%<\/strong> and 10%<\/strong>, excluding any revenue from COVID-19 testing-related activities. This positivity reflects the company\u2019s solid market position and strategic planning moving forward.<\/p>\n Despite the strong earnings report, Abbott’s stock was down 0.7%<\/strong> in premarket trading. However, it\u2019s noteworthy that the company’s stock has shown resilience, gaining 5.4%<\/strong> in 2024 thus far, while the S&P 500 index has witnessed a substantial increase of 21.9%<\/strong> in the same period.<\/p>\n CEO Robert B. Ford expressed optimism regarding the company’s future during a statement, saying, \u201cWe\u2019re well-positioned to achieve the upper end of our initial guidance ranges for the year and have great momentum heading into next year.\u201d<\/p>\n Abbott Laboratories’ third-quarter performance highlights its effective navigation through a challenging market landscape, especially within its medical devices segment. As the company continues to adapt and improve its product offerings, stakeholders can remain hopeful about its growth trajectory and financial health in the coming quarters.<\/p>\n","protected":false},"excerpt":{"rendered":" Abbott Laboratories Surpasses Q3 Expectations and Optimizes Full-Year Forecast Abbott Laboratories, a key player in the healthcare products sector, reported robust third-quarter results on Wednesday, exceeding market expectations in both sales and earnings. This positive performance was largely attributed to the company’s thriving medical-devices division. The Abbott Park, Illinois-based company has also raised its earnings…<\/p>\n","protected":false},"author":32,"featured_media":8920,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_eb_attr":"","footnotes":""},"categories":[685],"tags":[],"class_list":["post-8921","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma-stocks"],"_links":{"self":[{"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/posts\/8921","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/comments?post=8921"}],"version-history":[{"count":0,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/posts\/8921\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/media\/8920"}],"wp:attachment":[{"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/media?parent=8921"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/categories?post=8921"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/tags?post=8921"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Performance of Major Segments<\/h2>\n
Revised Financial Guidance<\/h2>\n
Market Reactions and Outlook<\/h2>\n
Conclusion<\/h2>\n